Publications found:
36,694
Sort by:
Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direc...
July 2022
259 pages
Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide...
July 2022
518 pages
Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide E...
July 2022
161 pages
Eosinophilic Esophagitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Eosinophilic Esophagitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipel...
July 2022
86 pages
Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline...
July 2022
136 pages
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY...
July 2022
54 pages
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key P...
July 2022
100 pages
Gastroenteritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Gastroenteritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide...
July 2022
64 pages
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Up...
July 2022
51 pages
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update...
July 2022
42 pages
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key P...
July 2022
65 pages
Guillain-Barre Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Guillain-Barre Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeli...
July 2022
83 pages
Haemophilus Influenzae Type B Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Haemophilus Influenzae Type B Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthca...
July 2022
57 pages
Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hep...
July 2022
71 pages
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Accordin...
July 2022
83 pages
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Ty...
July 2022
62 pages
Japanese Encephalitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Japanese Encephalitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline...
July 2022
41 pages
Kidney Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Kidney Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide...
July 2022
122 pages
Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disea...
July 2022
138 pages
Low Back Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Low Back Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide L...
July 2022
110 pages
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUM...
July 2022
38 pages
Measles Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Measles Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Measles...
July 2022
48 pages
Melanocortin Receptor 4 (MC4R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Melanocortin Receptor 4 (MC4R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Melanocortin Receptor 4 (MC4R) pipeline Targe...
July 2022
66 pages
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SU...
July 2022
63 pages
Narcolepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Narcolepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narc...
July 2022
109 pages
Neisseria Meningitidis Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Neisseria Meningitidis Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare dise...
July 2022
130 pages
Neurofibromatoses Type II Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Neurofibromatoses Type II Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipe...
July 2022
37 pages
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022...
July 2022
57 pages
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Orexin Recepto...
July 2022
74 pages
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Orexin Recepto...
July 2022
84 pages
Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline g...
July 2022
240 pages
Overactive Bladder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Overactive Bladder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline gu...
July 2022
128 pages
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,500.00
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline gui...
July 2022
3237 pages
Peanut Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Peanut Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide...
July 2022
136 pages
Polycystic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Polycystic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipe...
July 2022
109 pages
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Ph...
July 2022
179 pages
Retinopathy of Prematurity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Retinopathy of Prematurity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pip...
July 2022
67 pages
Rett Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Rett Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide R...
July 2022
110 pages
Rosacea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Rosacea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea...
July 2022
85 pages
Sickle Cell Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,500.00
Sickle Cell Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline g...
July 2022
277 pages
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 3,500.00
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Typ...
July 2022
55 pages
Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,500.00
Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline gu...
July 2022
714 pages
Vitiligo Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Vitiligo Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vitili...
July 2022
124 pages
Yellow Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
US$ 2,000.00
Yellow Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ye...
July 2022
92 pages
Investigation Report on China's Infliximab Market 2022-2031
US$ 3,200.00
... ankylosing spondylitis and Crohn's disease. By Oct. 2018, China's Infliximab market is monopolized by Remicade imported by Xi'an Janssen Pharmaceutical ... spondylitis and Crohn's disease in China Sales of Infliximab in China Prices of Infliximab in China Forecast on China's Infliximab market from 2018 to 2022
July 2022
40 pages
Research Report on China's Nicorandil Market, 2022-2031
US$ 3,600.00
In China, the crude incidence rate of hypertension among residents over the age of 18 is close to 30%, and the most common hazard of hypertension is coronary heart disease. By the end of 2021, it is e...
July 2022
50 pages
ADC Contract Manufacturing Market (5th Edition) by Phase of Development (Phase I, Phase II and Phase III), Scale of Operation (Clinical and Commercial), Type of Component Manufacturing (Antibody Manufacturing, HPAPI / Cytotoxic Payload, Linker and Conjugation Manufacturing, and Fill / Finish), Target Indications (Solid Tumors, Hematological Malignancies and Others), Type of Payload (Maytansinoid, Auristatin, Camptothecin, PBD and Others), Type of Linker (SMCC, VC, Malemide, Peptide Linker and Others), Type of Antibody Origin (Humanized, Chimeric, Murine, Human and Others), Antibody Isotype (IgG1and Others) and Geography (North America, Europe, Asia-Pacific and Rest of the World), 2022-2035
US$ 4,799.00
The ADC contract manufacturing market is expected to reach USD 2.8 billion by 2022 anticipated to grow at a CAGR of 11.8% during the forecast period 2022-2035. Over the past two decades, antibody ther...
July 2022
464 pages
